Get the Stockscreener App
2.4174
3.88%
0.0974
Nrx Pharmaceuticals Inc stock is traded at $2.4174, with a volume of 229.62K.
It is up +3.88% in the last 24 hours and down -24.92% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.32
Open:
$2.37
24h Volume:
229.62K
Relative Volume:
0.81
Market Cap:
$47.15M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.6044
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-8.71%
1M Performance:
-24.92%
6M Performance:
-18.03%
1Y Performance:
+17.56%
1-Day Range:
$2.3001
$2.45
1-Week Range:
$2.3001
$2.68
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.4174 | 49.15M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.22 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.00 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.90 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
643.00 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.04 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustai - Newport Daily News
Is NRx Pharmaceuticals Inc. Equity Warrant stock a value trapChannel Breakout Watchlist - newsyoung.net
Why Small-Cap Biotech NRx Pharmaceuticals Is Drawing Heavy Retail Buzz - Stocktwits
$3 Billion Suicidal Depression Market May Soon be Accessible via - openPR.com
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 - GlobeNewswire
FDA Grants NRX-100 Fast Track Designation for Suicidal Ideation - HCPLive
NRx Pharmaceuticals stock price target raised to $21 by BTIG on FDA progress - Investing.com India
FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients With Depression, Including Bipolar Depression - Psychiatric Times
FDA grants fast track designation for NRx’s depression treatment By Investing.com - Investing.com Australia
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation - ACCESS Newswire
Nrx Pharmaceuticals shares rise 3.17% premarket after FDA granted designation for NRX-100, expanding addressable population. - AInvest
NRx Pharma Receives FDA Fast Track Designation for NRX-100 for Treating Suicidal Ideation in Depression - AInvest
FDA grants fast track designation to NRx for suicidal ideation drug - Investing.com
NRX Pharmaceuticals: D. Boral Capital maintains Buy, PT raised to $31. - AInvest
NRx Pharmaceuticals and the Regulatory Catalysts Reshaping Mental Health Innovation - AInvest
FDA grants NRX-100 "unmet need" designation for treating 13 million Americans with suicidal thoughts. - AInvest
NRx Pharmaceuticals Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression Patients - AInvest
FDA Fast Track Breakthrough: NRX-100 Shows 63% Success Rate in Suicidal Depression Treatment - Stock Titan
NRX Pharmaceuticals WRT NRXPW 2025Q2 Earnings Preview Upside Potential on New Product Launch - AInvest
NRX Pharmaceuticals NRXP 2025Q2 Earnings Preview Upside Potential Driven by New Product Launch - AInvest
Is a relief rally coming for NRx Pharmaceuticals Inc. Equity Warrant holdersSmart Stock Forecast Using AI Algorithms - Newser
NRx Pharmaceuticals Inc. stock trend outlook and recovery pathReal Chart Based Opportunity Identification - Newser
Using R and stats models for NRx Pharmaceuticals Inc. forecastingFree Breakout Confirmation With Entry Tracker - Newser
How to recover losses in NRx Pharmaceuticals Inc. Equity Warrant stockAI Stock Movement Forecast with Accuracy - Newser
Can machine learning forecast NRx Pharmaceuticals Inc. recoveryShort-Term Price Breakout Signal Analysis - Newser
Key metrics from NRx Pharmaceuticals Inc.’s quarterly dataPredictable Return Strategy with AI Support - Newser
Combining machine learning predictions for NRx Pharmaceuticals Inc. Equity WarrantGrowth Watchlist for Long Term Positioning - Newser
What machine learning models say about NRx Pharmaceuticals Inc. Equity WarrantFree Smart Trend Trading with Weekly Signals - Newser
Is NRx Pharmaceuticals Inc. stock bottoming outFree Risk Controlled Short Term Trade Plans - Newser
Relative strength of NRx Pharmaceuticals Inc. Equity Warrant in sector analysisTechnical Safety Zone Pattern Recognition - Newser
Bloomberg to Air New to The Street Episode #683 Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - AInvest
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - ACCESS Newswire
NRx Pharmaceuticals Receives Final Approval to Acquire Dura Medical, Enhancing Mental Health Services in Florida - AInvest
New Product Launches: Will They Boost NRx Pharmaceuticals Inc. Equity Warrant Stock in 2025Capital Safe Picks with Consistent Gains - Newser
Key resistance and support levels for NRx Pharmaceuticals Inc. Equity WarrantBuy Entry Confirmation Based on Technical Analysis - Newser
Trend analysis for NRx Pharmaceuticals Inc. this weekGrowth Summary Based on Market Positioning - Newser
Can NRx Pharmaceuticals Inc. recover in the next quarterTechnical Insight Guide for Safer Trades - Newser
Multi factor analysis applied to NRx Pharmaceuticals Inc. Equity WarrantBuy Point Strategy with Profit Protection - Newser
Is NRx Pharmaceuticals Inc. showing signs of accumulationFast Movement Forecast for Trading Success - Newser
Technical analysis overview for NRx Pharmaceuticals Inc. stockEntry Optimization Guide with Volume Analysis - Newser
Applying chart zones and confluence areas to NRx Pharmaceuticals Inc.Expert-Backed High Yield Stock Watchlist - Newser
NRx Pharmaceuticals Inc. Equity Warrant Company’s Quarterly Earnings Growth: What the Numbers SayFree Smart Money Tracking Signal Generator - Newser
Nrx Pharmaceuticals shares rise 1.19% after-hours following AHCA approval for Dura Medical acquisition. - AInvest
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition - ADVFN Brasil
HOPE Therapeutics receives Florida approval for Dura Medical acquisition By Investing.com - Investing.com Nigeria
NRx Secures Florida Approval to Acquire Veterans Mental Health Provider Dura Medical - Stock Titan
Forecasting NRx Pharmaceuticals Inc. price range with options dataFree Trade Scanner With Buy Zone Alerts - Newser
NRx Pharmaceuticals Inc. stock chart pattern explainedFree Swing Trading Entry Point Signals - Newser
Statistical indicators supporting NRx Pharmaceuticals Inc.’s strengthMomentum Entry Alerts with Risk Control - Newser
NRX Pharmaceuticals Maintains 'Buy' Rating with $31.00 Price Target - AInvest
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
2.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):